Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: Altered expression and signal in immune cells

Arthritis and Rheumatism

Volumn 58, Issue 4, 2008, Pages 1010-1019

  Delgado, Mario ^a   Robledo, Gema ^a   Rueda, Bianca ^a   Varela, Nieves ^a   O'Valle, Francisco ^b   Hernandez Cortes, Pedro ^c   Caro, Marta ^a   Orozco, Gisela ^a   Gonzalez Rey, Elena ^d   Martin, Javier ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COLLAGEN TYPE 2; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 2;

AGONIST; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE EXACERBATION; DISEASE PREDISPOSITION; FLOW CYTOMETRY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HISTOCHEMISTRY; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TH1 CELL;

ADULT; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MICE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE, TYPE II; RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; VASOACTIVE INTESTINAL PEPTIDE;

EID: 42449095810     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23482     Document Type: Article

References (25)

1. Orozco G, Rueda B, Martin J. Genetic basis of rheumatoid arthritis. Biomed Pharmacother 2006;60:656-62.
2. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56:249-90.
3. Gonzalez-Rey E, Chorny A, Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat Rev Immunol 2007;7:52-63.
4. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13:241-51.
5. Pozo D, Gonzalez-Rey E, Chorny A, Anderson P, Varela N, Delgado M. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides 2007;28:1833-46.
6. Bangale Y, Karle S, Planque S, Zhou YX, Taguchi H, Nishiyama Y, et al. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J 2003;17:628-35.
7. Larsson J, Ekblom A, Henriksson K, Lundeberg T, Theodorsson E. Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis. Scand J Rheumatol 1991;20:326-35.
8. Cunningham S, O'Doherty C, Patterson C, McDonnell G, Hawkins S, Marrosu MG, et al. The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. J Neuroimmunol 2007;183:207-13.
9. Sun W, Hong J, Zang YC, Liu X, Zhang JZ. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis. Int Immunol 2006;18:1691-700.
10. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by down-regulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7:563-8.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
12. Takeba Y, Suzuki N, Kaneko A, Asai T, Sakane T. Evidence for neural regulation of inflammatory synovial cell functions by secreting calcitonin gene-related peptide and vasoactive intestinal peptide in patients with rheumatoid arthritis. Arthritis Rheum 1999;42:2418-29.
13. Sreedharan SP, Huang JX, Cheung MC, Goetzl EJ. Structure, expression, and chromosomal localization of the type I human vasoactive intestinal peptide receptor gene. Proc Natl Acad Sci U S A 1995;92:2939-43.
14. Williams RO. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 2002;46:271-3.
15. Gourlet P, Vandermeers A, Vertongen P, Ratche J, De Neef P, Cnudde J, et al. Development of high affinity selective VIP1 receptor agonists. Peptides 1997;18:1539-45.
16. Xia M, Sreedharan SP, Bolin DR, Gaufo GO, Goetzl EJ. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J Pharmacol Exp Ther 1997;281:629-33.
17. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
18. Morgan ME, Flierman R, van Duivenvoorde LM, Witteveen HJ, van Ewijk W, van Laar JM, et al. Effective treatment of collagen-induced arthritis by adoptive transfer of CD25+ regulatory T cells. Arthritis Rheum 2005;52:2212-21.
19. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis. Arthritis Rheum 2006;54:864-76.
20. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-6.
21. Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor. FASEB J 2001;15:2489-96.
22. 2 receptor for vasoactive intestinal peptide. Proc Natl Acad Sci U S A 2001;98:13854-9.
23. Voice J, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003;170:308-14.
24. Scherr M, Eder M. Gene silencing by small regulatory RNAs in mammalian cells. Cell Cycle 2007;6:444-9.
25. Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Bio 2006;71:523-30.